| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Rat |
| Target | nerve growth factor |
| Clinical data | |
| Synonyms | NV-01 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6496H10022N1756O2052S48 |
| Molar mass | 147.1 g/mol |
Ranevetmab (NV-01) (INN [1] ) is a veterinary monoclonal antibody designed for the treatment of pain associated with osteoarthritis in dogs.
Veterinary medicine is the branch of medicine that deals with the prevention, diagnosis and treatment of disease, disorder and injury in animals. The scope of veterinary medicine is wide, covering all animal species, both domesticated and wild, with a wide range of conditions which can affect different species.
Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and underlying bone. The most common symptoms are joint pain and stiffness. Initially, symptoms may occur only following exercise, but over time they may become constant. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are those near the ends of the fingers, at the base of the thumb, neck, lower back, knee, and hips. Joints on one side of the body are often more affected than those on the other. Usually the symptoms develop over some years. They can affect work and normal daily activities. Unlike other types of arthritis, only the joints are typically affected.
The domestic dog is a member of the genus Canis (canines), which forms part of the wolf-like canids, and is the most widely abundant terrestrial carnivore. The dog and the extant gray wolf are sister taxa as modern wolves are not closely related to the wolves that were first domesticated, which implies that the direct ancestor of the dog is extinct. The dog was the first species to be domesticated and has been selectively bred over millennia for various behaviors, sensory capabilities, and physical attributes.
This drug was developed by Nexvet Australia. [2]
